About the Company
protara therapeutics, inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. the company's lead program is tara-002, an investigational cell therapy for the treatment of lymphatic malformations. it also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. the company was formerly known as artara therapeutics, inc. and changed its name to protara therapeutics, inc. in may 2020. protara therapeutics, inc. is based in new york, new york.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TARA News
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H 2024Preliminary ...
Buy Rating on Protara Therapeutics Backed by Promising TARA-002 Clinical Trials and Significant Market Opportunity
In a report released today, Stacy Ku from TD Cowen maintained a Buy rating on Protara Therapeutics (TARA – Research Report), with a price ...
Analysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cadrenal Therapeutics, Inc. (CVKD – Research Report), Protara Therapeutics (TARA – Research Report) and Spruce ...
Protara Therapeutics: Q4 Earnings Snapshot
NEW YORK — NEW YORK — Protara Therapeutics, Inc. (TARA) on Wednesday reported a loss of $10.2 million in its fourth quarter. The New York-based company said it had a loss of 90 cents per share. For ...
Earnings Outlook For Relmada Therapeutics
Analysts estimate that Relmada Therapeutics will report an earnings per share (EPS) of $-0.83. Relmada Therapeutics bulls ...
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Sarepta Therapeutics ( SRPT 1.48%) could have a serious new competitor on the horizon. According to some fresh clinical data ...
Loading the latest forecasts...